Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiotoxicity and capecitabine: a case report.

Marybeth Singer1

  • 1mbs500@aol.com

Clinical Journal of Oncology Nursing
|March 13, 2003
PubMed
Summary

Oral fluoropyrimidines, used in cancer treatment, can cause rare cardiotoxicity. This complication, often presenting as chest pain, is typically reversible and warrants careful patient monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis: Common Side Effect.

Clinical journal of oncology nursing·2021
Same author

Oncology Nurse Practitioner Role: Recommendations From the Oncology Nursing Society's Nurse Practitioner Summit.

Clinical journal of oncology nursing·2018
Same author

Promoting High-Quality Cancer Care and Equity Through Disciplinary Diversity in Team Composition.

Journal of oncology practice·2016
Same author

Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer.

Breast cancer research and treatment·2013
Same author

Standardized method for quantification of developing lymphedema in patients treated for breast cancer.

International journal of radiation oncology, biology, physics·2010
Same author

Lymphedema in breast cancer: dilemmas and challenges.

Clinical journal of oncology nursing·2009

Area of Science:

  • Oncology
  • Cardiology

Background:

  • Oral fluoropyrimidines are emerging as a significant treatment modality for various cancers, including breast and colorectal cancer.
  • These drugs are engineered to deliver 5-fluorouracil (5-FU) selectively to tumor sites.

Observation:

  • Cardiotoxicity is an infrequent but serious adverse event linked to 5-FU and oral fluoropyrimidine therapies.
  • Chest pain is the predominant symptom reported in patients experiencing this complication.

Findings:

  • The cardiotoxicity associated with these agents can often be managed, with symptoms showing partial or complete resolution.
  • A case study details a patient's experience with capecitabine-induced cardiotoxicity.

Implications:

  • Understanding and recognizing fluoropyrimidine-induced cardiotoxicity is crucial for oncologists and healthcare providers.
  • Prompt diagnosis and management can improve patient outcomes and treatment adherence for cancer patients receiving these therapies.

Related Experiment Videos